Moderna Co-Founder, AI Pioneer Join Cellular Intelligence Board

Cellular Intelligence, a company focused on developing AI models to predict and control cellular behavior for faster and cheaper drug development, announced significant additions to its scientific advisory board on Monday. The company aims to leverage AI's pattern-recognition capabilities, similar to those used in predicting text or images, to understand how cells respond to various signals. By feeding AI models extensive data on cellular responses, Cellular Intelligence seeks to predict desired cellular outcomes without the need for exhaustive manual laboratory testing, a process that has historically been slow and costly, particularly for cell therapies.

Among the new appointees are Robert "Bob" Langer, a co-founder of Moderna and a renowned medical researcher, and Yann LeCun, a Turing Award-winning AI researcher. Langer will also serve as an observer on the company's board of directors. The inclusion of LeCun, who brings extensive AI expertise without a direct biology background, alongside Langer, who possesses deep medical research experience but no AI background, highlights Cellular Intelligence's strategy to integrate diverse scientific disciplines. This pairing is intended to demonstrate the company's commitment to robust expertise in both AI and biology.

Also joining the scientific advisory board are Jens Nielsen, CEO of the Novo Nordisk Foundation’s BioInnovation Institute, and Fabian Theis, a computational biologist and director of the Computational Health Center at Helmholtz Munich. These appointments further bolster the company's interdisciplinary approach. Cellular Intelligence CEO Micha Breakstone stated that these additions align with the company's foundational principle, which he described as "a marriage of three disciplines: genomics, developmental biology and AI." Breakstone emphasized that a "world model" can learn a system's behavior and predict its future states.

Langer expressed his confidence in the team, stating that his primary concern is whether the science can lead to tangible patient benefits and if the involved individuals can execute the vision. Having been in the field for over 50 years, Langer considers Micha Breakstone and the scientific team he has assembled to be among the best he has encountered. The company's ambition is to create AI models that can predict and ultimately control the behavior of living cells, a paradigm shift from traditional drug discovery methods that rely heavily on trial-and-error experimentation. This initiative is particularly relevant for developing new medicines, especially cell therapies, which involve complex biological systems.